Pascal Neuville has a PhD in molecular biology from University of Strasbourg, France. He spent five years at the University of Geneva as a post doc and then as Assistant Professor. Pascal then joined Transgene SA as an R&D project leader. From 2002 to 2008, he was CSO of Faust Pharmaceuticals SA, a drug discovery and development company in CNS. He founded Domain Therapeutics in 2008. From 2008 to 2010, Pascal was President of Alsace BioValley's Board of Directors, the life science competitiveness cluster of Alsace, and continued as a board member from 2010 to 2014. He is also a member of the investment committee of SATT CONECTUS, the private TTO of the University of Strasbourg and regional research institutions, and sits on the boards of Axilum Robotics and Defymed.
Ashley Nagle has a chemistry background and holds an MBA from University of Lincoln (UK). He spent six years at Lonza Biologics where he was initially in charge of negotiating and running contracts for product manufacture before being appointed Commercial Development Manager for EU and JP. Ashley then joined Almac Sciences as Business Development Manager and successfully led the acquisition of a peptide business and opened the Japanese market. He was then appointed Senior Business Development Director of Fulcrum Pharma Ltd where he led the EU business development team, spanning acquisition of new business areas and alliance management. During the past six years, Ashley managed the EU subsidiary of OncoSynergy (previously NexGenix), overseeing the product and business strategy, as a member of the senior management team of this US-based biotech company.
Stephan Schann has a PhD in Medicinal Chemistry from University of Strasbourg, France. In 2001, he joined EvotecOAI, Abingdon, UK where he held a position of team leader. From 2003 to 2008 he worked at Faust Pharmaceuticals where he set up and headed the Medicinal Chemistry Department. Since 2008, Stephan has been Head of Research at Domain Therapeutics and supervises research and collaboration agreements, as well as internal programs and the evolution of the drug discovery platform.
Marjorie Sidhoum has a PhD in Molecular and Cellular Biology from University of Strasbourg, France. In 2005, she trained in the design and management of clinical trials and worked with leading KOLS in the Onco-Hematology area until 2007. From 2008, Marjorie led the incubation and incorporation of Almetis, a spin-off of the University of Strasbourg, dedicated to the discovery of innovative medicines in oncology. In parallel, she graduated from HEC Challenge Plus, a program for the management of innovative projects. In 2010, she co-founded Almetis and managed the corporate and business development activities. Marjorie joined Domain Therapeutics as Business Development Manager in January 2013.
Christel Franchet has a PhD in Molecular and Cellular Biology from University de Strasbourg, France and carried out her postdoctoral position at Hoffmann La Roche. She left Hoffmann La Roche in 2001 to co-found Euroclide. At Euroclide, Christel was in charge of developing the GPCR technology that was acquired by Faust Pharmaceuticals and is currently exploited by Domain Therapeutics under the name DTect-All™. Christel then joined the company in 2003 and is in charge of supervising the DTect-All™ GPCR platform and High Throughput Screening activities.